# OnCo record pomalidomide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pomalidomide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pomalidomide" ;
  schema:name "Pomalidomide"@en ;
  schema:description "The third-generation thalidomide analogue for myeloma that has failed lenalidomide, and since 2020 the first new drug for Kaposi sarcoma in two decades."@en ;
  schema:url <https://onco.cc/drugs/pomalidomide/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pomalidomide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7227206> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pomalidomide> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Oral cereblon E3 ligase modulator (IMiD)" ;
  schema:alternateName "Pomalyst / Imnovid" ;
  onco:approval "US 2013: Multiple myeloma after ≥2 therapies including lenalidomide and a proteasome inhibitor", "US 2020: Kaposi sarcoma (AIDS-related after ART failure; HIV-negative)", "EU 2013: Relapsed/refractory multiple myeloma" ;
  onco:acceleratedApproval "US 2013-02-08: Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy", "US 2020-05-14: Treatment of patients with AIDS-related Kaposi’s Sarcoma after failure of highly active antiretroviral therapy (HAART).", "US 2020-05-14: Treatment of Kaposi’s Sarcoma in patients who are HIV-negative" ;
  onco:acceleratedApprovalConfirmed "US 2015-04-23: Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/kaposi-sarcoma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/ikzf1/>, <https://onco.cc/targets/ikzf3/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/natco/> ;
  onco:trials <https://onco.cc/trials/nct05730036/>, <https://onco.cc/trials/nct06464991/>, <https://onco.cc/trials/nct06956170/>, <https://onco.cc/trials/nct05438043/>, <https://onco.cc/trials/nct05572515/>, <https://onco.cc/trials/nct06152575/>, <https://onco.cc/trials/nct03539744/>, <https://onco.cc/trials/nct05519085/>, <https://onco.cc/trials/nct06413498/>, <https://onco.cc/trials/nct06158841/>, <https://onco.cc/trials/nct05020236/>, <https://onco.cc/trials/nct06208150/>, <https://onco.cc/trials/nct05455320/>, <https://onco.cc/trials/nct02343042/>, <https://onco.cc/trials/nct04068597/>, <https://onco.cc/trials/nct06953960/>, <https://onco.cc/trials/nct07227311/>, <https://onco.cc/trials/nct07018050/>, <https://onco.cc/trials/nct06106945/>, <https://onco.cc/trials/nct05714839/>, <https://onco.cc/trials/nct04973605/>, <https://onco.cc/trials/nct07150104/>, <https://onco.cc/trials/nct07742215/> .